Conditions · Pancreatic cancer
Pancreatic cancer — frontier options in California
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Biospecimen Collection · Computed Tomography · Core Biopsy — 1 site
- TRIALPHASE2RECRUITING
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Riluzole · Placebo — 1 site
- TRIALPHASE1RECRUITING
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NT-112: Autologous, engineered T Cells targeting KRAS G12D · AZD0240: Autologous, engineered T Cells targeting KRAS G12D — 18 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AMXI-5001:Dose Escalation Phase I · AMXI-5001:Dose Expansion Phase II — 4 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Setidegrasib · Oxaliplatin · Leucovorin — 48 sites
- TRIALPHASE2RECRUITING
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Autogene cevumeran · Atezolizumab · mFOLFIRINOX — 89 sites
- TRIALNANOT_YET_RECRUITING
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
Actigraphy · Online Mindfulness Meditation · Smartphone Application-based Intervention — 1 site
- TRIALPHASE1RECRUITING
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
XL309 · Olaparib — 16 sites
- TRIALPHASE3RECRUITING
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Kinisoquin™ · Placebo — 3 sites
- TRIALNARECRUITING
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
PICO G2 4k — 1 site
- TRIALPHASE2RECRUITING
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AZD0901 · 5-Fluorouracil · Leucovorin — 52 sites
- TRIALPHASE1RECRUITING
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RMC-9805 · RMC-6236 — 17 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Elironrasib · Daraxonrasib — 55 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
daraxonrasib — 257 sites
- TRIALPHASE1RECRUITING
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-1255 Dose Escalation · RSC-1255 Dose Expansion — 3 sites
- TRIALNARECRUITING
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Receive technology-based supportive cancer care · Receive redesigned team-based supportive cancer care — 17 sites
- TRIALPHASE2RECRUITING
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Biospecimen Collection · Computed Tomography · Magnetic Resonance Imaging — 454 sites
- TRIALEARLY_PHASE1RECRUITING
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. — 1 site
- TRIALPHASE3RECRUITING
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Atebimetinib · GnP · mGnP — 38 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
VS-7375 · Cetuximab · Carboplatin + Pemetrexed + Pembrolizumab — 14 sites
- TRIALPHASE1RECRUITING
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDE892 · IDE397 — 17 sites
- TRIALPHASE1NOT_YET_RECRUITING
IKS04 Regimen in Advanced Solid Tumors That Express CA242
IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody — 4 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
MT-4561 — 6 sites
- TRIALPHASE1RECRUITING
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
Biospecimen Collection · Cholestyramine · Computed Tomography — 1 site
- TRIALNARECRUITING
To Evaluate the Preliminary Efficacy of Our Digitally Enhanced CHW-led Intervention in Newly Diagnosed PDAC
PAL-CHW-PDAC · Usual Care with Attention Control — 1 site
- TRIALPHASE2RECRUITING
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Pemigatinib · Computed Tomography (CT) · Magnetic Resonance Imaging — 109 sites
- TRIALPHASE3RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RYZ101 · Everolimus · Sunitinib — 54 sites
- TRIALPHASE1RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 · Pembrolizumab · Panitumumab — 39 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 — 6 sites
- TRIALPHASE1RECRUITING
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
STRO-004 · Pembrolizumab — 9 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.